Cholesterol Treatment Trialists Collaboration statin
Statin reduces the 5-year incidence of major coronary events, coronary revascularization, and stroke by about a fifth per mmol/L reduction in LDL, largely irrespective of initial lipid profile or other baseline characteristics
IMPROVE-IT ezetimabe
Adding a non-statin lipid-modifying agent in concert with a statin improves CV outcomes in addition to enhancing lipid lowering effects
The subset of patients with DM had a higher rate of major vascular events than patients without DM (46 vs. 31%)
CV mortality, major CV event, or nonfatal stroke:
34.7% ( sim mono ) vs 32.7% (sim + Ezt) (HR 0.94 ; P=0.016; NNT 50)
FOURIER evolocumab
Evolocumab on a background statin therapy lowered LDL to a median of 30 mg /dL and reduced the risk of cardiovascular events
Patients with ASCVD benefit from the lowering of LDL below current targets
There were reductions of 21 to 27% in the risk of MI, stroke, coronary revascularization
NO effect on cardiovascular mortality.